Company Overview
About Ansa Biotechnologies
Ansa Biotechnologies is a synthetic DNA synthesis company developing enzymatic DNA writing technology to overcome the length and quality limitations of chemical DNA synthesis. Founded in 2021 and headquartered in Emeryville, California, Ansa uses engineered terminal deoxynucleotidyl transferase (TdT) enzymes rather than phosphoramidite chemistry to build DNA strands, enabling synthesis of longer sequences with higher fidelity and fewer toxic reagents. The company emerged from research at UC Berkeley and Lawrence Berkeley National Laboratory.
Business Model & Competitive Advantage
The company raised $68 million in Series B funding in 2023, backed by investors including Data Collective (DCVC), The Engine, and Andreessen Horowitz Bio, to commercialize its enzymatic synthesis platform. Ansa's technology is particularly relevant for applications requiring long DNA fragments — synthetic biology gene construction, therapeutic oligonucleotides, and data storage — where conventional synthesis reaches length and error-rate ceilings. By 2024-2025, the company has been delivering custom DNA synthesis orders to pharmaceutical, agricultural biotech, and research customers.
Competitive Landscape 2025–2026
In 2025, Ansa Biotechnologies operates at a critical juncture in synthetic biology infrastructure, as the field requires DNA synthesis capabilities far exceeding what chemical methods can reliably deliver. The company competes with Twist Bioscience, Integrated DNA Technologies (IDT), and emerging enzymatic competitors like DNA Script. Ansa's 2025-2026 priorities include scaling throughput, pursuing FDA engagement for therapeutic oligonucleotide applications, and expanding into DNA data storage partnerships where unprecedented sequence lengths are commercially valuable.
Recent Activity
View all →Quarterly Report filed 2026-08-07
Material Event filed 2026-08-05
Key Differentiators
Strong Challenger
Ansa Biotechnologies is an established challenger with significant market presence and competitive offerings in Healthcare.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Epic Systems
Epic Systems Corporation was founded in 1979 by Judith Faulkner and is headquartered in Verona, Wisconsin, remaining privately held with Faulkner as majority owner. The company develops large-scale el
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Pfizer
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The compan
Moderna
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stép
Amgen
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologic
Veeva Systems
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv
Compare Ansa Biotechnologies with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Ansa Biotechnologies? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Ansa Biotechnologies Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Ansa Biotechnologies vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →